Andrea K. Mccollum

Array ( [id] => 9971158 [patent_doc_number] => 09018168 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2015-04-28 [patent_title] => 'Therapeutic method for treating congestive heart failure' [patent_app_type] => utility [patent_app_number] => 14/000789 [patent_app_country] => US [patent_app_date] => 2011-08-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 8192 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 28 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14000789 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9042316 [patent_doc_number] => 20130244954 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-09-19 [patent_title] => 'USE OF REG4 AND PHARMACEUTICAL COMPOSITION THEREOF' [patent_app_type] => utility [patent_app_number] => 13/816484 [patent_app_country] => US [patent_app_date] => 2011-08-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 8332 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13816484 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8962989 [patent_doc_number] => 20130202591 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-08-08 [patent_title] => 'ANTIBODIES DIRECTED AGAINST IL-17' [patent_app_type] => utility [patent_app_number] => 13/814262 [patent_app_country] => US [patent_app_date] => 2011-08-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 14970 [patent_no_of_claims] => 58 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13814262 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9238689 [patent_doc_number] => 08603478 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2013-12-10 [patent_title] => 'Anti-RON antibodies' [patent_app_type] => utility [patent_app_number] => 13/177071 [patent_app_country] => US [patent_app_date] => 2011-07-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 19 [patent_figures_cnt] => 23 [patent_no_of_words] => 30186 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 42 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13177071 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8209020 [patent_doc_number] => 20120128687 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-05-24 [patent_title] => 'NOVEL ANTIBODY FORMULATION' [patent_app_type] => utility [patent_app_number] => 13/168635 [patent_app_country] => US [patent_app_date] => 2011-06-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6458 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0128/20120128687.pdf [firstpage_image] =>[orig_patent_app_number] => 13168635 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8884751 [patent_doc_number] => 20130157935 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-06-20 [patent_title] => 'GLUCAGON ANALOGUES' [patent_app_type] => utility [patent_app_number] => 13/702841 [patent_app_country] => US [patent_app_date] => 2011-06-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 12033 [patent_no_of_claims] => 27 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13702841 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8891069 [patent_doc_number] => 20130164253 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-06-27 [patent_title] => 'Long-Term Storage of Non-Glycosylated Recombinant Human G-CSF' [patent_app_type] => utility [patent_app_number] => 13/805180 [patent_app_country] => US [patent_app_date] => 2011-06-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 5947 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13805180 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9676889 [patent_doc_number] => 08815798 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2014-08-26 [patent_title] => 'Insulin analogues containing additional disulfide bonds' [patent_app_type] => utility [patent_app_number] => 13/805503 [patent_app_country] => US [patent_app_date] => 2011-06-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 26556 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 179 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13805503 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7502228 [patent_doc_number] => 20110263831 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-10-27 [patent_title] => 'NUCLEAR FACTOR kappaB INDUCING FACTOR' [patent_app_type] => utility [patent_app_number] => 13/157815 [patent_app_country] => US [patent_app_date] => 2011-06-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 21132 [patent_no_of_claims] => 3 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0263/20110263831.pdf [firstpage_image] =>[orig_patent_app_number] => 13157815 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10869818 [patent_doc_number] => 08895011 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2014-11-25 [patent_title] => 'Insulin-resistance-improving drug' [patent_app_type] => utility [patent_app_number] => 13/699876 [patent_app_country] => US [patent_app_date] => 2011-05-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 10769 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 45 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13699876 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8989273 [patent_doc_number] => 20130216554 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-08-22 [patent_title] => 'Methods for Producing Enteroendocrine Cells That Make and Secrete Insulin' [patent_app_type] => utility [patent_app_number] => 13/697792 [patent_app_country] => US [patent_app_date] => 2011-05-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 24 [patent_figures_cnt] => 24 [patent_no_of_words] => 27302 [patent_no_of_claims] => 44 [patent_no_of_ind_claims] => 10 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13697792 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8720200 [patent_doc_number] => 20130071417 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-03-21 [patent_title] => 'N-DOMAIN OF CARCINOEMBRYONIC ANTIGEN AND COMPOSITIONS, METHODS AND USES THEREOF' [patent_app_type] => utility [patent_app_number] => 13/697295 [patent_app_country] => US [patent_app_date] => 2011-05-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 29 [patent_figures_cnt] => 29 [patent_no_of_words] => 23174 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 11 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13697295 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12486750 [patent_doc_number] => 09993521 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-06-12 [patent_title] => Modulation of scleraxis using a dominant negative scleraxis mutant with a basic DNA-binding domain deletion [patent_app_type] => utility [patent_app_number] => 13/583402 [patent_app_country] => US [patent_app_date] => 2011-05-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 16 [patent_no_of_words] => 6346 [patent_no_of_claims] => 2 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 30 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13583402 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8927902 [patent_doc_number] => 20130183662 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-07-18 [patent_title] => 'MEANS AND METHODS FOR IDENTIFYING AN INCREASED RISK OF SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) PATIENTS FOR DEVELOPING RENAL MANIFESTATIONS' [patent_app_type] => utility [patent_app_number] => 13/642568 [patent_app_country] => US [patent_app_date] => 2011-04-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 21 [patent_figures_cnt] => 21 [patent_no_of_words] => 18655 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13642568 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8815365 [patent_doc_number] => 20130116410 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-05-09 [patent_title] => 'NEW STABILIZING AGENT FOR PHARMACEUTICAL PROTEINS' [patent_app_type] => utility [patent_app_number] => 13/642020 [patent_app_country] => US [patent_app_date] => 2011-04-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4975 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13642020 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10142249 [patent_doc_number] => 09175048 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2015-11-03 [patent_title] => 'Use of peptides as transporters intended for the internalization of molecules of interest into target cells' [patent_app_type] => utility [patent_app_number] => 13/643598 [patent_app_country] => US [patent_app_date] => 2011-04-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 28 [patent_no_of_words] => 16516 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 84 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13643598 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8768242 [patent_doc_number] => 20130096279 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-04-18 [patent_title] => 'PROCESS FOR THE PURIFICATION OF A GROWTH FACTOR PROTEIN' [patent_app_type] => utility [patent_app_number] => 13/638244 [patent_app_country] => US [patent_app_date] => 2011-03-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 10669 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13638244 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8585673 [patent_doc_number] => 20130004494 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-01-03 [patent_title] => 'Inhibition of P21 and Use Thereof for Inducing Tissue Regeneration' [patent_app_type] => utility [patent_app_number] => 13/583777 [patent_app_country] => US [patent_app_date] => 2011-03-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5579 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13583777 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8828715 [patent_doc_number] => 20130129760 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-05-23 [patent_title] => 'Polypeptides' [patent_app_type] => utility [patent_app_number] => 13/578969 [patent_app_country] => US [patent_app_date] => 2011-02-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 15030 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13578969 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10506325 [patent_doc_number] => 09234192 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-01-12 [patent_title] => 'Conjugated proteins' [patent_app_type] => utility [patent_app_number] => 13/575207 [patent_app_country] => US [patent_app_date] => 2011-02-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18869 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 66 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13575207 [rel_patent_id] =>[rel_patent_doc_number] =>)